New Onset Guttate Psoriasis Following Pandemic H1N1 Influenza Vaccination

Moon Seub Shin, Soo Jin Kim, Seong Hyun Kim, Yee Gyoung Kwak, Hai-Jin Park

Department of Dermatology, Division of Infectious Disease, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea

Since the introduction of H1N1 influenza vaccine in the wake of the 2009 H1N1 pandemic, many serious and non-serious vaccine-related adverse events have been reported. The vaccination could induce pain, erythema, tenderness, and induration on injected areas. These symptoms usually disappear in a few days after the vaccination. In this case, we observed a 26-year-old woman with multiple erythematous scaly macules scattered on the extremities and trunk. She was injected with an inactivated split-virus influenza A/H1N1 vaccine without adjuvant (Greenflu-S®, Green Cross Corp.) on her left deltoid area 10 days earlier. The first lesion appeared on the injection site three days after the vaccination, and the following lesions spread to the trunk and extremities after a few days. Histopathological examinations showed neutrophilic collections within the parakeratotic cornified layer, moderate acanthosis, diminished granular layer, elongation and edema of the dermal papillae, and dilated capillaries. The lesions were successfully treated with topical steroids and ultraviolet B phototherapy within three weeks, and there was no relapse for the following fourteen months. We assumed that pandemic vaccination was an important trigger for the onset of guttate psoriasis in this case. (Ann Dermatol 25(4) 489~492, 2013)

Keywords: Psoriasis, Vaccination

INTRODUCTION

Psoriasis, which is one of the most common inflammatory skin disorders, is characterized by the self-perpetuating activation of autoimmune T cells. Infection is an important trigger for both the onset and exacerbations of psoriasis. However, there are only a few reports in the literature describing the new onset of psoriasis following the administration of vaccine1-6. The pandemic influenza A (H1N1) vaccine was widely used in Korea to fight the influenza pandemics in 2009. However, there have been a number of cases reported on the adverse events, including, but not limited to, the pain, erythema, tenderness, and induration on the injected areas7. These reports also indicated that these events were usually resolved within a few days after the vaccination.

In this study, a 26-year-old woman developed guttate psoriasis initially on the vaccination site three days after the injection of an inactivated split-virus influenza A/H1N1 vaccine (Greenflu-S®; Green Cross Corp., Yong-in, Korea).

CASE REPORT

A 26-year-old Korean female was presented with guttate psoriasis-like lesions of multiple erythematous scaly macules scattered on her extremities and trunk (Fig. 1A). She was injected with an inactivated split-virus influenza A/H1N1 vaccine without adjuvant (Greenflu-S®) on her left deltoid area ten days before the visit to our department. The first lesion appeared on the injection site three days after the vaccination, and its size slowly increased...
Fig. 1. (A) Multiple erythematous small scaly macules on trunk. (B) Larger lesion at the site of vaccination.

Fig. 2. (A) Skin biopsy specimen showed parakeratosis, moderate acanthosis and rete ridge elongation in epidermis and perivascular infiltration of inflammatory cells in upper dermis (H&E, ×100). (B) Neutrophilic collection within the parakeratotic cornified layer, Munro’s microabscess (H&E, ×200).

(Fig. 1B). After a few days, multiple small scaly macules developed on the trunk and extremities. On the lesion on her back, an Auspitz sign was observed when silvery scales were removed. She suffered appendicitis four months before the vaccination and had no history of any other inflammatory disorders. There was no personal or family history of psoriasis. Routine laboratory investigation results were within the normal range of limits except for anti-streptolysin-O (ASO) titer, which elevated to 773 IU/ml (normal: <200 IU/ml). However, there was no definite history of streptococcal infection, such as pharyngitis. Histopathological examination showed neutrophilic collections within the parakeratotic cornified layer, moderate acanthosis, diminished granular layer, elongation and edema of the dermal papillae, and dilated capillaries (Fig. 2). The lesions were successfully treated with topical steroids and ultraviolet B phototherapy within three weeks. And for the following fourteen months, there was no relapse.

DISCUSSION

Infection is an important trigger for both the onset and exacerbations of psoriasis. However, there are only a few reports in the literature describing the new onset of psoriasis following vaccination. The onset of guttate psoriasis is developed at the site of vaccination against smallpox and influenza, as well as with diphtheria and antistreptococcal sera which was reported in 1955. BCG vaccination has also been reported to cause guttate psoriasis-like eruptions and psoriatic arthropathy. The reported cases are summarized in Table 1. However, psoriasis followed by influenza vaccination is rare although some cases of pityriasis rosea developed after H1N1 vaccination or concurrent influenza A (H1N1) infection were reported.
Psoriasis Following Influenza Vaccination

Table 1. Summary of reported cases of psoriasis following vaccination

| Case No. | Age/Sex | Vaccination | PMHx | Psoriasis history | Disease onset | Skin lesions |
|----------|---------|-------------|------|------------------|---------------|--------------|
| Case 1   | 3 yr/M  | BCG*        | Bladder cancer | + | After seventh session (9-week course of weekly treatment) | Plaques psoriasis with psoriatic arthropathy |
| Case 2   | 4 yr/M  | BCG         | -    | - (father, uncle: +) | 1 week later | Guttate psoriasis |
| Case 3   | 5 yr/M  | BCG*        | Bladder cancer | - | After sixth session | Guttate psoriasis with psoriatic arthropathy |
| Case 4   | 6 mo/F  | BCG         | Congenital mitral valve insufficiency | - | 1 month later | Plaque psoriasis |

PMHx: past medical history, M: male, F: female, BCG: bacillus Calmette-Guerin, +: present, -: absent. *BCG immunotherapy for bladder cancer. †Interval between the use of vaccination and the appearance of psoriasis lesions.

The atiological relationship between psoriasis and vaccination is still uncertain. Researchers hypothesizes that the development of psoriasis following BCG vaccination is caused by the induction of a T helper type 1 (Th1) predominant response. The amplified cytokines include interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), granulocyte macrophage-colony stimulating factor (GM-CSF), and interleukins (ILs)-1, 2, 5, 6, 8, 10, 12, and 18. This response may form the basis of the development for psoriasis; a Th1-dominant disease in genetically predisposes individuals, where IFN-γ, TNF-α, GM-CSF and IL-6 promote epidermal proliferation, and IL-8 stimulates neutrophil ingestion.

In South Korea, a monovalent, unconjugated, inactivated, split-virus influenza A (H1N1) vaccine, was widely used in 2009 during the pandemic breakout of the H1N1 influenza. The vaccine contained split-virus products of 15 μg of hemagglutinin antigen per 0.5 ml prefilled syringe. The most common local adverse events from influenza vaccination were pain, redness, tenderness, and swelling around the injected area. These issues were resolved in a few days after vaccination in most cases.

Currently, it is thought that the pathological mechanisms responsible for psoriasis are related to IL-22, Th17 cell-derived cytokine, which is a key player in the development of characteristic epidermal changes of psoriasis. In the study of influenza vaccine in a murine model, the cytokine profile demonstrated a robust cellular immune response with enhanced Th1 and Th17 immunity that provided balanced immunity against both intracellular and extracellular forms of the virus.

There were other factors we considered when diagnosing that the psoriasis in this case was triggered by influenza vaccination. The patient showed an elevated level of ASO titer, which indicated that there was a previous streptococcal infection. However, the exacerbation of psoriasis following streptococcal infections usually occurs within two to three weeks. In addition, ASO antibody can be found in the blood within weeks or months after the streptococcal infection has cured. So, it was also hard to conclude that streptococcal infection, not the vaccine, was the real cause of psoriasis in this case when there was no definite history of recent infections. Therefore, the first lesion developed on the injection area was suspected as a Koebner phenomenon, but the lesions spread on to the other sites of the body could not be explained by Koebnerization. One possible explanation is that H1N1 vaccination acted as a co-stimulant in carriers or patients with subclinical infections rather than the sole cause of guttate psoriasis. However, we could not find any similar reports to our case.

In conclusion, although the patient in this case showed an elevated level of ASO titer, we believed that the role of the H1N1 vaccination in the development of guttate psoriasis should not be ruled out.

REFERENCES

1. Raaschou-Nielsen W. Psoriasis vaccinalis; report of two cases, one following B.C.G. vaccination and one following vaccination against influenza. Acta Derm Venereol 1955;35:37-42.
2. Bogdaszewska-Czabanowska, Brzewski M. Psoriasis vaccinalis (post-BCG). Przegl Dermatol 1973;60:497-499.
3. Queiro R, Ballina J, Weruaga A, Fernández JA, Riestra JL, Torre JC, et al. Psoriatic arthropathy after BCG immunotherapy for bladder carcinoma. Br J Rheumatol 1995;34:1097.
4. Koca R, Altinayar HC, Numanoğlu G, Uralacak M. Guttate psoriasis-like lesions following BCG vaccination. J Trop Pediatr 2004;50:178-179.
5. Dudelzak J, Curtis AR, Sheehan DJ, Lesher JL Jr. New-onset psoriasis and psoriatic arthritis in a patient treated with Bacillus Calmette-Guérin (BCG) immunotherapy. J Drugs Dermatol 2008;7:684.
6. Takayama K, Satoh T, Hayashi M, Yokozeki H. Psoriatic skin lesions induced by BCG vaccination. Acta Derm Venereol 2008;88:621-622.
7. Oh CE, Lee J, Kang JH, Hong YJ, Kim YK, Cheong HJ, et al.
Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial. Vaccine 2010;28:5857-5863.

8. Mubki TF, Bin Dayel SA, Kadry R. A case of Pityriasis rosea concurrent with the novel influenza A (H1N1) infection. Pediatr Dermatol 2011;28:341-342.

9. Kwon NH, Kim JE, Cho BK, Park HJ. A novel influenza a (H1N1) virus as a possible cause of pityriasis rosea? J Eur Acad Dermatol Venereol 2011;25:368-369.

10. Chen JF, Chiang CP, Chen YF, Wang WM. Pityriasis rosea following influenza (H1N1) vaccination. J Chin Med Assoc 2011;74:280-282.

11. Böhle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. Philadelphia: Elsevier Saunders, 2012:135-156.

12. Bolognia J, Jorizzo JL, Schaffer JV. Dermatology. 3rd ed. Philadelphia: Elsevier Saunders, 2012:135-156.

13. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445:648-651.

14. Hamouda T, Chepurnov A, Mank N, Knowlton J, Chepurnova T, Myc A, et al. Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model. Hum Vaccin 2010;6:585-594.

15. Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992;128:39-42.

16. MedlinePlus: Trusted Health Information for you [Internet]. Bethesda (MD): National Library of Medicine (US); Anti-streptolysin O titer; [updated 2011 Aug 29; cited 2011 Sep 1]. Available from: http://www.nlm.nih.gov/medlineplus/ency/article/003522.htm